MM 151

Drug Profile

MM 151

Alternative Names: MM-151

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Jan 2017 MM 151 is available for licensing as of 08 Jan 2017. www.merrimack.com
  • 08 Jan 2017 Merrimack Pharmaceuticals terminates phase I/II trial in Colocrectal cancer in USA
  • 08 Aug 2016 Merrimack Pharmaceuticals plans a part II of a phase I trial for IGF-1-positive and KRAS/NRAS-mutant Solid tumours (Combination therapy, Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top